Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2025
New cystic fibrosis drug fast tracked for NHS use
15 July 2025 - Some people with cystic fibrosis are set to benefit from a new once daily triple therapy treatment, ...
Posted by Michael Wonder on 20 Jun 2025
UNAIDS urges Gilead to drop price of new HIV prevention shot
18 June 2025 - The US FDA has approved long-acting injectable lenacapavir for HIV prevention. The new medicine is administered ...
Posted by Michael Wonder on 19 Jun 2025
Bayer files for approval of gadoquatrane in the US
17 June 2025 - Bayer today announced the submission of a new drug application to the US FDA for its ...
Posted by Michael Wonder on 19 Jun 2025
Final draft guidance finds benefits of two treatments for patients with Alzheimer’s disease remain too small to justify the additional cost to the NHS
19 June 2025 - The benefits from donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai) - remain too small to justify ...
Posted by Michael Wonder on 19 Jun 2025
Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy
19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of ...
Posted by Michael Wonder on 19 Jun 2025
Atezolizumab for the adjuvant treatment of patients with resected non-small-cell lung cancer
19 June 2025 - NICE has published final evidence-based recommendations on the use of atezolizumab (Tecentriq) for the adjuvant treatment ...
Posted by Michael Wonder on 19 Jun 2025
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
16 June 2025 - With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be ...
Posted by Michael Wonder on 19 Jun 2025
Kye Pharmaceuticals receives Health Canada approval for new dosing guidance for Firdapse and an additional paediatric indication
17 June 2025 - Kye Pharmaceuticals today announced that Health Canada has approved its supplemental new drug submission regarding the recommended ...
Posted by Michael Wonder on 19 Jun 2025
Health Canada approves Novartis' Kisqali for HR positive, HER2 negative early breast cancer patients at high risk of recurrence
18 June 2025 - Health Canada approval is based on the pivotal Phase 3 NATALEE trial data, which demonstrated a clinically ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC funding U turn for patients
16 June 2025 - Associate Health Minister David Seymour says the oestradiol patch funding decision is an example of PHARMAC’s ...
Posted by Michael Wonder on 18 Jun 2025
PHARMAC to fund two brands of oestradiol patches from 1 December 2025
16 June 2025 - PHARMAC will fund two brands of oestradiol patches – Estradot and Estradiol TDP Mylan – from ...
Posted by Michael Wonder on 18 Jun 2025
FDA to issue new Commissioner’s national priority vouchers to companies supporting US national interests
17 June 2025 - The US FDA today announced its Commissioner’s National Priority Voucher program to enhance the health interests of ...
Posted by Michael Wonder on 18 Jun 2025
Aldeyra Therapeutics resubmits reproxalap new drug application for the treatment of dry eye disease
17 June 2025 - Aldeyra Therapeutics today announced the resubmission of a new drug application to the US FDA for ...
Posted by Michael Wonder on 18 Jun 2025
Cancer inhibitors scrapped from basic insurance for some users
18 June 2025 - National health care institute Zorginstituut Nederland has scrapped several cancer inhibiting drugs from the basic health ...
Posted by Michael Wonder on 18 Jun 2025
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
18 June 2025 - Today, the FDA approved tafasitamab-cxix (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or ...
Posted by Michael Wonder on 18 Jun 2025
Yeztugo (lenacapavir) is now the first and only FDA approved HIV prevention option offering 6 months of protection
18 June 2025 - Approval based on Phase 3 PURPOSE 1 and PURPOSE 2 data that showed ≥99.9% of participants remained ...